Proinflammatory cytokine suppression (null)

"Proinflammatory cytokine suppression" is not a specific molecule, receptor, or canonical therapeutic target. Instead, it refers to the process or strategy of inhibiting the activity or production of proinflammatory cytokines—signaling proteins such as interleukin 1 (IL‑1), IL‑6, tumor necrosis factor alpha (TNF‑α), and interferon gamma (IFNγ)—which are secreted by immune cells like T helper cells and macrophages to promote inflammation[4][5]. Suppression of these cytokines is a therapeutic approach used in various inflammatory and autoimmune diseases to reduce excessive immune responses that can lead to tissue damage. Drugs such as monoclonal antibodies may be designed to neutralize these cytokines or block their receptors[4][5]. However, "proinflammatory cytokine suppression" itself does not refer to a single molecular entity but rather an immunomodulatory intervention strategy. An inflammatory cytokine or proinflammatory cytokine is a type of signaling molecule that promotes inflammation; therapies targeting them include monoclonal antibodies that neutralize either the molecules themselves or their receptors[4]. Because this entry describes an action/process rather than a discrete molecular target, it should be flagged as incorrect for structured target databases.

null